Clinical Trial Update: Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating whole-body HER3 quantification using radiolabeled patritumab deruxtecan (HER3-DXd) PET/CT in non-small cell lung cancer, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Squamous Cell Carcinoma
• Non-small Cell Lung Cancer

Drugs mentioned

• Patritumab Deruxtecan (HER3-DXd) (patritumab deruxtecan)

Snippet

Sponsor: The Netherlands Cancer Institute | Conditions: Non-Small Cell Lung Carcinoma, Advanced Non-Small Cell Squamous Lung Cancer | Phase 2 | Status: RECRUITING